Susquehanna International Group’s TRACON Pharmaceuticals, Inc. Common Stock TCON Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q2 | – | Sell |
-3,893
| Closed | -$33.5K | – | 13499 |
|
|
2024
Q1 | $33.5K | Buy |
+3,893
| New | +$18.6K | ﹤0.01% | 11684 |
|
|
2023
Q4 | – | Sell |
-792
| Closed | -$2.82K | – | 13541 |
|
|
2023
Q3 | $2.82K | Buy |
+792
| New | +$4.25K | ﹤0.01% | 11824 |
|
|
2023
Q2 | – | Sell |
-2,094
| Closed | -$79.1K | – | 13441 |
|
|
2023
Q1 | $79.1K | Buy |
+2,094
| New | +$68.6K | ﹤0.01% | 11437 |
|
|
2022
Q4 | – | Sell |
-646
| Closed | -$22K | – | 14029 |
|
|
2022
Q3 | $22K | Buy |
+646
| New | +$24.7K | ﹤0.01% | 12578 |
|
|
2022
Q1 | – | Sell |
-986
| Closed | -$49.6K | – | 14216 |
|
|
2021
Q4 | $55K | Buy |
+986
| New | +$62.9K | ﹤0.01% | 12502 |
|
|
2021
Q2 | – | Sell |
-629
| Closed | -$87K | – | 13432 |
|
|
2021
Q1 | $104K | Buy |
+629
| New | +$121K | ﹤0.01% | 11844 |
|
|
2019
Q3 | – | Sell |
-192
| Closed | -$26K | – | 10981 |
|
|
2019
Q2 | $26K | Buy |
+192
| New | +$30.4K | ﹤0.01% | 9973 |
|
|
2019
Q1 | – | Sell |
-217
| Closed | -$27K | – | 10060 |
|
|
2018
Q4 | $27K | Buy |
217
+162
| +295% | +$44K | ﹤0.01% | 8635 |
|
|
2018
Q3 | $22K | Sell |
55
-44
| -44% | -$20.4K | ﹤0.01% | 8987 |
|
|
2018
Q2 | $53K | Sell |
99
-18
| -15% | -$9.57K | ﹤0.01% | 9260 |
|
|
2018
Q1 | $54K | Buy |
+117
| New | +$63.8K | ﹤0.01% | 8929 |
|
|
2015
Q2 | – | Sell |
-62
| Closed | -$173K | – | 10543 |
|
|
2015
Q1 | $173K | Buy |
+62
| New | +$163K | ﹤0.01% | 8733 |
|
Other funds holding TCON
Susquehanna International Group's TCON Position: Q2 2024 in Review
Susquehanna International Group sold out of TRACON Pharmaceuticals, Inc. Common Stock (TCON) in Q2 2024, closing a stake of 3,893 shares — an estimated $33.5K sold.
Susquehanna International Group first reported a position in TCON in Q1 2015 and held it in 12 quarters. The position peaked at $173K in Q1 2015. 1 fund tracked by Wall St. Rank holds TCON as of Q2 2024.
- Susquehanna International Group reported no remaining TRACON Pharmaceuticals, Inc. Common Stock position as of Q2 2024 after selling out during the quarter.
- Susquehanna International Group sold 3,893 TRACON Pharmaceuticals, Inc. Common Stock shares in Q2 2024, an estimated $33.5K.
- Susquehanna International Group first reported a position in TRACON Pharmaceuticals, Inc. Common Stock in Q1 2015 and held it in 12 quarters.
- Susquehanna International Group's TRACON Pharmaceuticals, Inc. Common Stock position peaked at $173K in Q1 2015.
- 1 fund tracked by Wall St. Rank held TRACON Pharmaceuticals, Inc. Common Stock as of Q2 2024.
Based on Susquehanna International Group's 13F filing for Q2 2024, filed 15 Aug 2024.